Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2
Upon determination of eligibility, all patients will be receive:
Trastuzumab + Vinorelbine + Docetaxel
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
feasibility and toxicity of the combination of weekly docetaxel, vinorelbine, and trastuzumab in patients with metastatic breast cancer who overexpress Her-2.
18 Months
No
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Institutional Review Board
SCRI BRE 46
NCT00193089
April 2001
September 2009
Name | Location |
---|